Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.

Journal of neurology·2026
Same author

No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy.

Journal of the neurological sciences·2026
Same author

The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.

Journal of neurology·2026
Same author

Deep Learning Framework for Automated MRI Planimetry in Multiple Sclerosis.

International journal of biomedical imaging·2026
Same author

Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases.

JAMA neurology·2026
Same author

Kappa free light chain index in CSF diagnostics: the impact of different immunoglobulin isotypes.

Frontiers in immunology·2026
Same journal

Evaluation and management of pulmonary nodules: state-of-the-art and future perspectives.

Expert opinion on medical diagnostics·2013
Same journal

Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Expert opinion on medical diagnostics·2013
Same journal

The molecular landscape of diffuse glioma and prospects for biomarker development.

Expert opinion on medical diagnostics·2013
Same journal

Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?

Expert opinion on medical diagnostics·2013
Same journal

Promising biomarkers for systemic lupus erythematosus.

Expert opinion on medical diagnostics·2013
Same journal

Challenges of COPD diagnosis.

Expert opinion on medical diagnostics·2013
See all related articles

Related Experiment Video

Updated: May 13, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Diagnostic biomarkers in multiple sclerosis.

Bettina Kuenz1, Florian Deisenhammer, Thomas Berger

  • 1Innsbruck Medical University, Clinical Department of Neurology, Anichstrasse 35, A-6020 Innsbruck, Austria +43 512/504 24363 ; +43 512/504 24266 ; markus.reindl@i-med.ac.at.

Expert Opinion on Medical Diagnostics
|March 16, 2013
PubMed
Summary
This summary is machine-generated.

Diagnosing multiple sclerosis (MS) is challenging due to its varied presentations. This review covers key biomarkers like MRI and CSF analysis to improve patient stratification and tailored therapies for MS.

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neuroimmunology
  • Neurology
  • Clinical Diagnostics

Background:

  • Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS).
  • MS presents with heterogeneous clinical, histopathologic, immunologic, and neuroradiologic features, complicating diagnosis and treatment stratification.
  • Accurate patient typing is crucial for predicting disease course and tailoring therapies.

Purpose of the Study:

  • To review major diagnostic biomarkers currently recommended for multiple sclerosis.
  • To highlight the importance of differentiated MS patient typing for therapeutic strategies.

Main Methods:

  • Review of current literature on MS diagnostic biomarkers.
  • Analysis of recommended diagnostic tools including magnetic resonance imaging (MRI).
  • Evaluation of cerebrospinal fluid (CSF) analysis and antibody testing.

Main Results:

  • Magnetic resonance imaging (MRI) is a key tool in MS diagnosis.
  • Cerebrospinal fluid (CSF) analysis provides important diagnostic parameters.
  • Antibodies against aquaporin-4 water channels and myelin antigens are relevant diagnostic markers.

Conclusions:

  • Effective diagnosis and typing of MS patients rely on a combination of advanced biomarkers.
  • Biomarker-guided stratification enables prediction of disease progression and personalized treatment approaches for MS.
  • Continued research into diagnostic biomarkers is essential for advancing MS care.